Or Eisenberg - 16 Jun 2026 Form 4 Insider Report for NeuroSense Therapeutics Ltd. (NRSN)

Reporting relationship: Chief Financial Officer
Issuer ticker: NRSN
Reported as of: 16 Jun 2026
Net transaction value: +$200,000
SEC form: 4
Accepted by SEC: 17 Jun 2026, 16:30:02 UTC
Prior SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Or Eisenberg

Key filing fact

Or Eisenberg filed Form 4 for NeuroSense Therapeutics Ltd. (NRSN) on 17 Jun 2026.

Key facts

This page summarizes Or Eisenberg's Form 4 filing for NeuroSense Therapeutics Ltd. (NRSN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: +$200,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001721412 Primary reporting owner

Eisenberg Or

Relationship: Chief Financial Officer
Address: C/O NEUROSENSE THERAPEUTICS LTD., 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, ISRAEL
Signature: /s/ Or Eisenberg
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRSN transaction

Ordinary Shares

Purchase

Transaction value: $200,000
Shares: +250,000
Change %: +20%
Price: $0.8000
Shares after: 1,504,050
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On June 16, 2026, the Reporting Person acquired 250,000 ordinary shares, no par value per share, of the Issuer at a purchase price of $0.80 per share, pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.